|
11.
|
|
9 p, 745.8 KB |
The EMIF-AD Multimodal Biomarker Discovery study : Design, methods and cohort characteristics
/
Bos, Isabelle (Maastricht University) ;
Vos, Stephanie (Maastricht University) ;
Vandenberghe, Rik (Katholieke Universiteit Leuven) ;
Scheltens, Philip (Amsterdam UMC. University Medical Center) ;
Engelborghs, Sebastiaan (University of Antwerp) ;
Frisoni, Giovanni (IRCCS Instituto Centro San Giovanni di Dio Fatebenefratelli) ;
Molinuevo, José Luis (Fundació Pasqual Maragall) ;
Wallin, Anders (Institute of Neuroscience and Physiology) ;
Lleó, Alberto (Institut d'Investigació Biomèdica Sant Pau) ;
Popp, Julius (Lausanne University Hospital) ;
Martinez-Lage, Pablo (Centro de Investigación y Tecnología Agroalimentaria de Aragón) ;
Baird, Alison (University of Oxford) ;
Dobson, Richard (NIHR University College London Hospitals) ;
Legido-Quigley, Cristina (King's College London) ;
Sleegers, Kristel (University of Antwerp) ;
Van Broeckhoven, Christine (University of Antwerp) ;
Bertram, Lars (University of Oslo) ;
Ten Kate, Mara (Amsterdam UMC. University Medical Center) ;
Barkhof, Frederik (Amsterdam UMC. University Medical Center) ;
Zetterberg, Henrik (UK Dementia Research Institute) ;
Lovestone, Simon (University of Oxford) ;
Streffer, Johannes (Janssen Pharmaceutical Companies) ;
Visser, Pieter Jelle (Vrije Universiteit Amsterdam) ;
Universitat Autònoma de Barcelona
There is an urgent need for novel, noninvasive biomarkers to diagnose Alzheimer's disease (AD) in the predementia stages and to predict the rate of decline. Therefore, we set up the European Medical Information Framework for Alzheimer's Disease Multimodal Biomarker Discovery (EMIF-AD MBD) study. [...]
2018 -  10.1186/s13195-018-0396-5
Alzheimer's research & therapy, Vol. 10 Núm. 1 (june 2018) , p. 64
|
|
|
12.
|
|
11 p, 814.5 KB |
Amyloid-β, Tau, and Cognition in Cognitively Normal Older Individuals : Examining the Necessity to Adjust for Biomarker Status in Normative Data
/
Bos, Isabelle (Maastricht University) ;
Vos, Stephanie J.B. (Maastricht University) ;
Jansen, Willemijn J. (Maastricht University) ;
Vandenberghe, Rik (KU Leuven) ;
Gabel, Silvy (KU Leuven) ;
Estanga, Ainara (CITA-Alzheimer Foundation) ;
Ecay-Torres, Mirian (CITA-Alzheimer Foundation) ;
Tomassen, Jori (Vrije Universiteit Amsterdam) ;
den Braber, Anouk (Vrije Universiteit Amsterdam) ;
Lleó, Alberto (Institut d'Investigació Biomèdica Sant Pau) ;
Sala, Isabel (Institut d'Investigació Biomèdica Sant Pau) ;
Wallin, Anders (University of Gothenburg Sahlgrenska Academy) ;
Kettunen, Petronella (University of Oxford) ;
Molinuevo, José Luis (Universitat Pompeu Fabra) ;
Rami, Lorena (Hopsital Clínic Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (IDIBAPS)) ;
Chetelat, Gaël (Université de Caen-Normandie GIP Cyceron) ;
de la Sayette, Vincent (CHU de Caen) ;
Tsolaki, Magda (AHEPA University Hospital (Grècia)) ;
Freund-Levi, Yvonne (Norrtälje Hospital Tiohundra) ;
Johannsen, Peter (University of Copenhagen) ;
Novak, Gerald P. (Janssen Pharmaceutical Research and Development) ;
Ramakers, Inez (Maastricht University) ;
Verhey, Frans R. (Maastricht University) ;
Visser, Pieter J. (Vrije Universiteit Amsterdam) ;
Universitat Autònoma de Barcelona
We investigated whether amyloid-β (Aβ) and tau affected cognition in cognitively normal (CN) individuals, and whether norms for neuropsychological tests based on biomarker-negative individuals would improve early detection of dementia. [...]
2018 - 10.3389/fnagi.2018.00193
Frontiers in aging neuroscience, Vol. 10 (25 2018) , p. 193
|
|
|
13.
|
|
12 p, 1.2 MB |
Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer's disease
/
Startin, Carla M. (LonDownS Consortium (London Down Syndrome Consortium)) ;
Ashton, Nicholas J. (University of Gothenburg) ;
Hamburg, Sarah (LonDownS Consortium (London Down Syndrome Consortium)) ;
Hithersay, Rosalyn (LonDownS Consortium (London Down Syndrome Consortium)) ;
Wiseman, Frances K. (University College London) ;
Mok, Kin Y. (Hong Kong University of Science and Technology) ;
Hardy, John (University College London) ;
Lleó, Alberto (Institut d'Investigació Biomèdica Sant Pau) ;
Lovestone, Simon (University of Oxford) ;
Parnetti, Lucilla (University of Perugia) ;
Zetterberg, Henrik (UCL Institute of Neurology (Regne Unit)) ;
Hye, Abdul (Maudsley NHS Foundation) ;
Fisher, Elisabeth ;
Nizetic, Dean ;
Tybulewicz, Victor ;
Karmiloff-Smith, Anette ;
Al-Janabi, Tamara ;
Zhang, David ;
Strydom, André (LonDownS Consortium (London Down Syndrome Consortium)) ;
Universitat Autònoma de Barcelona
Down syndrome (DS), caused by chromosome 21 trisomy, is associated with an ultra-high risk of dementia due to Alzheimer's disease (AD), driven by amyloid precursor protein (APP) gene triplication. Understanding relevant molecular differences between those with DS, those with sporadic AD (sAD) without DS, and controls will aid in understanding AD development in DS. [...]
2019 - 10.1186/s13195-019-0477-0
Alzheimer's research & therapy, Vol. 11 Núm. 1 (21 2019) , p. 26
|
|
|
14.
|
|
6 p, 731.5 KB |
A metabolite-based machine learning approach to diagnose Alzheimer-type dementia in blood : Results from the European Medical Information Framework for Alzheimer disease biomarker discovery cohort
/
Stamate, Daniel (University of London) ;
Kim, Min (Steno Diabetes Center Copenhagen) ;
Proitsi, Petroula (King's College London) ;
Westwood, Sarah (University of Oxford) ;
Baird, Alison (University of Oxford) ;
Nevado-Holgado, Alejo (University of Oxford) ;
Hye, Abdul (King's College London) ;
Bos, Isabelle (Amsterdam UMC) ;
Vos, Stephanie J.B. (Maastricht University) ;
Vandenberghe, Rik (Amsterdam UMC) ;
Teunissen, Charlotte E. (Amsterdam UMC. University Medical Center) ;
Kate, Mara Ten (Amsterdam UMC. University Medical Center) ;
Scheltens, Philip (Vrije Universiteit Amsterdam) ;
Gabel, Silvy (Laboratory for Cognitive Neurology) ;
Meersmans, Karen (Laboratory for Cognitive Neurology) ;
Blin, Olivier (Aix-Marseille Université) ;
Richardson, Jill (GlaxoSmithKline R&D) ;
De Roeck, Ellen (University of Antwerp) ;
Engelborghs, Sebastiaan (Vrije Universiteit Brussel (VUB)) ;
Sleegers, Kristel (Center for Molecular Neurology. VIB) ;
Bordet, Régis (University of Lille) ;
Ramit, Lorena (Hospital Clínic i Provincial de Barcelona) ;
Kettunen, Petronella (Sahlgrenska Academy at University of Gothenburg) ;
Tsolaki, Magda (AHEPA University Hospital (Grècia)) ;
Verhey, Frans (Maastricht University) ;
Alcolea, Daniel (Institut d'Investigació Biomèdica Sant Pau) ;
Lleó, Alberto (Institut d'Investigació Biomèdica Sant Pau) ;
Peyratout, Gwendoline (Lausanne University Hospital) ;
Tainta, Mikel (Fundacion CITA-alzheimer Fundazioa) ;
Johannsen, Peter (Copenhagen University Hospital) ;
Freund-Levi, Yvonne (Karolinska Institutet (Estocolm, Suècia)) ;
Frölich, Lutz (University of Heidelberg) ;
Dobricic, Valerija (University of Lübeck) ;
Frisoni, Giovanni B. (IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli) ;
Molinuevo, José Luis (Universitat Pompeu Fabra) ;
Wallin, Anders (Sahlgrenska Academy at the University of Gothenburg) ;
Popp, Julius (Geneva University Hospitals) ;
Martinez-Lage, Pablo (Fundación CITA-Alzhéimer Fundazioa) ;
Bertram, Lars (University of Oslo) ;
Blennow, Kaj (Sahlgrenska University Hospital (Suècia)) ;
Zetterberg, Henrik (UCL Institute of Neurology (Regne Unit)) ;
Streffer, Johannes (University of Antwerp) ;
Visser, Pieter J. (Amsterdam UMC) ;
Lovestone, Simon (Janssen-Cilag UK Ltd) ;
Legido-Quigley, Cristina (King's College London) ;
Universitat Autònoma de Barcelona
Machine learning (ML) may harbor the potential to capture the metabolic complexity in Alzheimer Disease (AD). Here we set out to test the performance of metabolites in blood to categorize AD when compared to CSF biomarkers. [...]
2019 - 10.1016/j.trci.2019.11.001
Alzheimer's & dementia, Vol. 5 (2019) , p. 933-938
|
|
|
15.
|
|
9 p, 1012.4 KB |
Plasma Aβ42/40 ratio alone or combined with FDG-PET can accurately predict amyloid-PET positivity : A cross-sectional analysis from the AB255 Study
/
Pérez-Grijalba, Virginia (Araclon Biotech S.L.) ;
Arbizu, Javier (Clínica Universidad de Navarra) ;
Romero, Judith (Araclon Biotech S.L.) ;
Prieto, Elena (Clínica Universidad de Navarra) ;
Pesini, Pedro (Araclon Biotech S.L.) ;
Sarasa, Leticia (Araclon Biotech S.L.) ;
Guillen, Fernando (Clínica Universidad de Navarra) ;
Monleón, Inmaculada (Araclon Biotech S.L.) ;
San-José, Itziar (Araclon Biotech S.L.) ;
Martínez-Lage, Pablo (Fundación CITA-Alzheimer) ;
Munuera, Josep (Institut de Recerca Sant Joan de Déu) ;
Hernández, Isabel (Instituto de Salud Carlos III) ;
Buendía, Mar (Universitat Internacional de Catalunya) ;
Sotolongo-Grau, Oscar (Universitat Internacional de Catalunya) ;
Alegret, Montserrat (Instituto de Salud Carlos III) ;
Ruiz, Agustín (Instituto de Salud Carlos III) ;
Tárraga, Lluís (Instituto de Salud Carlos III) ;
Boada, Mercè (Instituto de Salud Carlos III) ;
Sarasa, Manuel (Araclon Biotech S.L.) ;
Goñi Imízcoz, Miguel (Hospital Divino Vallés (Burgos)) ;
Pujadas, Francesc ;
Villarejo, Alberto ;
Frank, Ana ;
Peña-Casanova, Jordi ;
Fernández, Manuel ;
Piñol, Gerard ;
Blesa, Rafael (Institut d'Investigació Biomèdica Sant Pau) ;
Gil, Pedro ;
Pascual, Luis F. ;
Aguilar Barberà, Miquel ;
Frisoni, Giovanni B. ;
Matias-Guiu, Jorge ;
Andreasen, Niels ;
Antúnez, Carmen ;
Universitat Autònoma de Barcelona
To facilitate population screening and clinical trials of disease-modifying therapies for Alzheimer's disease, supportive biomarker information is necessary. This study was aimed to investigate the association of plasma amyloid-beta (Aβ) levels with the presence of pathological accumulation of Aβ in the brain measured by amyloid-PET. [...]
2019 - 10.1186/s13195-019-0549-1
Alzheimer's research & therapy, Vol. 11 Núm. 1 (january 2019) , p. 96
|
|
|
16.
|
|
22 p, 986.7 KB |
Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort
/
Kim, Min (Steno Diabetes Center Copenhagen) ;
Snowden, Stuart (University of Cambridge) ;
Suvitaival, Tommi (Steno Diabetes Center Copenhagen) ;
Ali, Ashfaq (Steno Diabetes Center Copenhagen) ;
Merkler, David J. (University of South Florida) ;
Ahmad, Tahmina (King's College London) ;
Westwood, Sarah (University of Oxford) ;
Baird, Alison (University of Oxford) ;
Proitsi, Petroula (King's College London) ;
Nevado-Holgado, Alejo (University of Oxford) ;
Hye, Abdul (Steno Diabetes Center Copenhagen) ;
Bos, Isabelle (Maastricht University) ;
Vos, Stephanie (Maastricht University) ;
Vandenberghe, Rik (University Hospitals Leuven (Bèlgica)) ;
Teunissen, Charlotte (Amsterdam Neuroscience) ;
ten Kate, Mara (Amsterdam Neuroscience) ;
Scheltens, Philip (Amsterdam UMC. University Medical Center) ;
Gabel, Silvy (KU Leuven) ;
Meersmans, Karen (KU Leuven) ;
Blin, Olivier ;
Richardson, Jill (GlaxoSmithKline R&D) ;
De Roeck, Ellen (University of Antwerp) ;
Sleegers, Kristel (VIB) ;
Bordet, Régis (University of Lille) ;
Rami Gonzalez, Lorena (Hospital Clínic i Provincial de Barcelona) ;
Kettunen, Petronella (John Radcliffe Hospital (Oxford, Regne Unit)) ;
Tsolaki, Magda (AHEPA University Hospital (Grècia)) ;
Verhey, Frans (Maastricht University) ;
Sala, Isabel (Institut d'Investigació Biomèdica Sant Pau) ;
Lleó, Alberto (Institut d'Investigació Biomèdica Sant Pau) ;
Peyratout, Gwendoline (Lausanne University Hospital) ;
Tainta, Mikel (CITA-Alzheimer Foundation) ;
Johannsen, Peter (Copenhagen University Hospital) ;
Freund-Levi, Yvonne (Karolinska University Hospital and Karolinska Institutet (Suecia)) ;
Frölich, Lutz (University of Heidelberg) ;
Dobricic, Valerija (University of Lübeck) ;
Engelborghs, Sebastiaan (University Hospital Antwerp (Bèlgica)) ;
Frisoni, Giovanni B. (University of Geneva) ;
Molinuevo, José Luis (Hospital Clínic i Provincial de Barcelona) ;
Wallin, Anders (University of Gothenburg) ;
Popp, Julius (Geneva University Hospitals) ;
Martinez-Lage, Pablo (CITA-Alzheimer Foundation) ;
Bertram, Lars (University of Lübeck) ;
Barkhof, Frederik (Amsterdam Neuroscience) ;
Ashton, Nicholas J (University of Gothenburg) ;
Blennow, Kaj (Sahlgrenska University Hospital (Suècia)) ;
Zetterberg, Henrik (UK Dementia Research Institute) ;
Streffer, Johannes (Janssen Pharmaceutical Companies) ;
Visser, Pieter J. (Amsterdam Neuroscience) ;
Lovestone, Simon (University of Oxford) ;
Legido-Quigley, Cristina (Steno Diabetes Center Copenhagen) ;
Universitat Autònoma de Barcelona
A critical and as-yet unmet need in Alzheimer's disease (AD) is the discovery of peripheral small molecule biomarkers. Given that brain pathology precedes clinical symptom onset, we set out to test whether metabolites in blood associated with pathology as indexed by cerebrospinal fluid (CSF) AD biomarkers. [...]
2019 - 10.1016/j.jalz.2019.03.004
Alzheimer's & Dementia, Vol. 15 Núm. 6 (june 2019) , p. 817-827
|
|
|
17.
|
|
13 p, 162.5 KB |
Validation of plasma proteomic biomarkers relating to brain amyloid burden in the EMIF-Alzheimer's disease multimodal biomarker discovery cohort
/
Westwood, Sarah (University of Oxford) ;
Baird, Alison L (University of Oxford) ;
Anand, Sneha N. (University of Oxford) ;
Nevado-Holgado, Alejo (University of Oxford) ;
Kormilitzin, Andrey (University of Oxford) ;
Shi, Liu (University of Oxford) ;
Hye, Abdul (King's College London) ;
Ashton, Nicholas J (University of Gothenburg) ;
Morgan, Angharad R. (Cardiff University) ;
Bos, Isabelle (Maastricht University) ;
Vos, Stephanie J.B. (Maastricht University) ;
Baker, Susan (Janssen R and D) ;
Buckley, Noel J (University of Oxford) ;
Ten Kate, Mara (Vrije Universiteit University Medical Center) ;
Scheltens, Philip (Vrije Universiteit University Medical Center) ;
Teunissen, Charlotte E. (Vrije Universiteit University Medical Center) ;
Vandenberghe, Rik (University Hospitals Leuven (Bèlgica)) ;
Gabel, Silvy (Ku Leuven) ;
Meersmans, Karen (Ku Leuven) ;
Engelborghs, Sebastiaan (Vrije Universiteit Brussel (VUB)) ;
De Roeck, Ellen E. (Vrije Universiteit Brussel (VUB)) ;
Sleegers, Kristel (Center for Molecular Neurology) ;
Frisoni, Giovanni B. (Irccs Istituto Centro San Giovanni di Dio Fatebenefratelli) ;
Blin, Olivier (Aix-Marseille Université) ;
Richardson, Jill C. (GlaxoSmithKline R and D) ;
Bordet, Régis (University of Lille) ;
Molinuevo, José Luis (Hospital Clínic i Provincial de Barcelona) ;
Rami, Lorena (Universitat Pompeu Fabra) ;
Wallin, Anders (Sahlgrenska Academy at University of Gothenburg) ;
Kettunen, Petronella (Sahlgrenska Academy at University of Gothenburg) ;
Tsolaki, Magda (AHEPA University Hospital (Grècia)) ;
Verhey, Frans (Maastricht University) ;
Lleó, Alberto (Institut d'Investigació Biomèdica Sant Pau) ;
Sala, Isabel (Institut d'Investigació Biomèdica Sant Pau) ;
Popp, Julius (Geneva University Hospitals) ;
Peyratout, Gwendoline (Lausanne University Hospital) ;
Martinez-Lage, Pablo (Geneva University Hospitals) ;
Tainta, Mikel (CITA-Alzheimer Foundation) ;
Johannsen, Peter (Copenhagen University Hospital) ;
Freund-Levi, Yvonne (Karolinska Institutet (Estocolm, Suècia)) ;
Frölich, Lutz (University of Heidelberg) ;
Dobricic, Valerija (University of Lübeck) ;
Legido-Quigley, Cristina (Steno Diabetes Center) ;
Bertram, Lars (University of Oslo) ;
Barkhof, Frederik (Ucl Institutes of Neurology and Healthcare Engineering) ;
Zetterberg, Henrik (Ucl Institute of Neurology) ;
Morgan, B.Paul (Cardiff University) ;
Streffer, Johannes (Janssen R and D. Llc) ;
Visser, Pieter Jelle (Vu University Medical Center) ;
Lovestone, Simon (Janssen R and D) ;
Universitat Autònoma de Barcelona
We have previously investigated, discovered, and replicated plasma protein biomarkers for use to triage potential trials participants for PET or cerebrospinal fluid measures of Alzheimer's disease (AD) pathology. [...]
2020 - 10.3233/JAD-190434
Journal of Alzheimer's disease, Vol. 74 Núm. 1 (2020) , p. 213-225
|
|
|
18.
|
|
9 p, 634.4 KB |
Cortical atrophy and amyloid and tau deposition in Down syndrome : A longitudinal study
/
Padilla, Concepción (Institut d'Investigació Biomèdica Sant Pau) ;
Montal, Victor (Institut d'Investigació Biomèdica Sant Pau) ;
Walpert, Madeleine J. (University of Cambridge. Cambridge Intellectual and Developmental Disabilities Research Group. Department of Psychiatry) ;
Hong, Young T. (University of Cambridge. Wolfson Brain Imaging Centre. Department of Clinical Neurosciences) ;
Fryer, Tim D. (University of Cambridge. Wolfson Brain Imaging Centre. Department of Clinical Neurosciences) ;
Coles, Jonathan (University of Cambridge. Division of Anaesthesia. Department of Medicine) ;
Aigbirhio, Franklin I. (University of Cambridge. Wolfson Brain Imaging Centre. Department of Clinical Neurosciences) ;
Hartley, Sigan L. (University of Wisconsin-Madison. Waisman Center) ;
Cohen, Ann (University of Pittsburgh. Department of Psychiatry) ;
Tudorascu, Dana L. (University of Pittsburgh. Department of Psychiatry) ;
Christian, Bradley T. (University of Wisconsin-Madison. Waisman Center) ;
Handen, Benjamin L. (University of Pittsburgh. Department of Psychiatry) ;
Klunk, William E. (University of Pittsburgh. Department of Psychiatry) ;
Holland, Anthony John (Cambridgeshire and Peterborough NHS Foundation Trust. Fulbourn Hospital) ;
Zaman, Shahid H. (Cambridgeshire and Peterborough NHS Foundation Trust. Fulbourn Hospital)
Introduction: The Down syndrome population has a high prevalence for dementia, often showing their first clinical symptoms in their 40s. Methods: In a longitudinal cohort, we investigate whether amyloid deposition at time point 1 (TP1) could predict cortical thickness change at time point 2 (TP2). [...]
2022 - 10.1002/dad2.12288
Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring, Vol. 14 Núm. 1 (2022) , p. e12288
|
|
|
19.
|
|
18 p, 2.0 MB |
Establishing In-House Cutoffs of CSF Alzheimer's Disease Biomarkers for the AT(N) Stratification of the Alzheimer Center Barcelona Cohort
/
Orellana, Adelina (Universitat Internacional de Catalunya. Ace Alzheimer Center Barcelona) ;
García-gonzález, Pablo (Universitat Internacional de Catalunya. Ace Alzheimer Center Barcelona) ;
Valero, Sergi (Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas) ;
Montrreal, Laura (Universitat Internacional de Catalunya. Ace Alzheimer Center Barcelona) ;
De Rojas, Itziar (Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas) ;
Hernández, Isabel (Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas) ;
Rosende-roca, Maitee (Universitat Internacional de Catalunya. Ace Alzheimer Center Barcelona) ;
Vargas, Liliana (Universitat Internacional de Catalunya. Ace Alzheimer Center Barcelona) ;
Tartari, Juan Pablo (Universitat Internacional de Catalunya. Ace Alzheimer Center Barcelona) ;
Esteban de Antonio, Ester (Universitat Internacional de Catalunya. Ace Alzheimer Center Barcelona) ;
Bojaryn, Urszula (Universitat Internacional de Catalunya. Ace Alzheimer Center Barcelona) ;
Narvaiza, Leire (Universitat Internacional de Catalunya. Ace Alzheimer Center Barcelona) ;
Alarcón-Martín, Emilio (Universitat Internacional de Catalunya. Ace Alzheimer Center Barcelona) ;
Alegret, Montserrat (Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas) ;
Alcolea, Daniel (Institut d'Investigació Biomèdica Sant Pau) ;
Lleó, Alberto (Institut d'Investigació Biomèdica Sant Pau) ;
Tárraga, Lluís (Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas) ;
Pytel, Vanesa (Universitat Internacional de Catalunya. Ace Alzheimer Center Barcelona) ;
Cano, Amanda (Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas) ;
Marquié, Marta. (Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas) ;
Boada, Mercè (Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas) ;
Ruiz, Agustín (Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas) ;
Universitat Autònoma de Barcelona
Background: Clinical diagnosis of Alzheimer's disease (AD) increasingly incorporates CSF biomarkers. However, due to the intrinsic variability of the immunodetection techniques used to measure these biomarkers, establishing in-house cutoffs defining the positivity/negativity of CSF biomarkers is recommended. [...]
2022 - 10.3390/ijms23136891
International journal of molecular sciences, Vol. 23 Núm. 13 (july 2022) , p. 6891
|
|
|
20.
|
|
16 p, 3.7 MB |
Altered brain metabolome is associated with memory impairment in the rTG4510 mouse model of tauopathy
/
Tondo, Mireia (Institut d'Investigació Biomèdica Sant Pau) ;
Wasek, Brandi (Baylor Scott & White Research Institute) ;
Escolà-Gil, Joan Carles (Institut d'Investigació Biomèdica Sant Pau) ;
Gonzalo Calvo, David de (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Harmon, Clinton (Baylor Scott & White Research Institute) ;
Arning, Erland (Baylor Scott & White Research Institute) ;
Bottiglieri, Teodoro (Baylor Scott & White Research Institute) ;
Universitat Autònoma de Barcelona
Alzheimer's disease (AD) is characterized, amongst other features, by the pathologic accumulation of abnormally phosphorylated tau filaments in neurons that lead to neurofibrillary tangles. However, the molecular mechanisms by which the abnormal processing of tau leads to neurodegeneration and cognitive impairment remain unknown. [...]
2020 - 10.3390/metabo10020069
Metabolites, Vol. 10 Núm. 2 (february 2020) , p. 69
|
|
visitante ::
identificación
alerta personal vía correo electrónico o subscríbase al 
canal RSS.
